List view / Grid view

Dr Douglas Clark (Boehringer Ingelheim)

 

article

Developing a holistic approach to cardio, metabolic and renal disease

With cardiovascular disease continuing to present a significant health concern,…

28 June 2022 | By

With cardiovascular disease continuing to present a significant health concern, European Pharmaceutical Review’s Hannah Balfour reflects on recent development efforts and drug approvals in the space with comment from Dr Douglas Clark, Head of Medical Affairs at Boehringer Ingelheim UK & Ireland.